share_log

Cancer-Focused Coeptis Therapeutics Turns To SPAC Deal To Uplist To NASDAQ

Cancer-Focused Coeptis Therapeutics Turns To SPAC Deal To Uplist To NASDAQ

专注于癌症的 Coeptis Therapeutics 转向 SPAC 交易向纳斯达克上市
Benzinga Real-time News ·  2022/04/20 15:50
  • Coeptis Therapeutics Inc (OTC:COEP) has agreed to a $175 million merger deal with Bull Horn Holdings Corporation (NASDAQ:BHSE), a special purpose acquisition company.
  • Upon completing the deal, Bull Horn will be rebranded and operate as Coeptis Therapeutics Holdings Inc. and is expected to be listed on Nasdaq under the ticker symbol COEP.
  • With this transaction, expected to be completed in the third quarter, the shareholders of Coeptis will receive equity in Bull Horn valued at $175 million.
  • Related: Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform.
  • The merger is anticipated to push Coeptis' efforts to boost its cell therapy platforms to treat cancer.
  • Coeptis is a developer of cell therapy platforms for cancer. Its product portfolio is highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is co-developing with VyGen-Bio Inc. 
  • CD38-GEAR-NK is a natural killer (NK) cell-based investigational therapeutic that enables combination therapy with anti-CD38 monoclonal antibodies (mAbs).
  • Coeptis' current President and CEO, David Mehalick, will lead the combined company as President & CEO. The current Chief Financial Officer of Bull Horn, Chris Calise, will join the post-closing Board of Directors.
  • Price Action: COEP shares are down 26.6% at $4.11 during the market session on the last check Wednesday.
  • Coeptis Therapeutic（场外交易代码：COEP）已同意与之达成1.75亿美元的合并协议牛角控股公司纳斯达克股票代码：BHSE），一家特殊目的收购公司。
  • 交易完成后，Bull Horn将更名为Coeptis Therapeutics Holdings Inc.，预计将在纳斯达克上市，股票代码为COEP。
  • 这笔交易预计将在第三季度完成，Coeptis的股东将获得价值1.75亿美元的Bull Horn股权。
  • 相关： Coeptis Therapeutics 打算收购 Statera 的 TLR5 激动剂平台。
  • 预计此次合并将推动Coeptis努力加强其治疗癌症的细胞疗法平台。
  • Coeptis 是癌症细胞疗法平台的开发商。其产品组合以细胞疗法技术（CD38-GEAR-NK）和针对CD38相关癌症的体外诊断（CD38-诊断）为亮点，Coeptis正在与该技术共同开发Vygen-Bio Inc。
  • CD38-GEAR-NK 是一种基于自然杀手 (NK) 细胞的研究性疗法，可与抗 CD38 单克隆抗体 (mAB) 联合治疗。
  • Coeptis现任总裁兼首席执行官戴维·梅哈里克将以总裁兼首席执行官的身份领导合并后的公司。Bull Horn现任首席财务官克里斯·卡利斯将在收盘后加入董事会。
  • 价格走势：在周三最后一次支票的市场交易中，COEP股价下跌26.6％，至4.11美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发